Chelsea's Northera Gets Another Chance

Investors betting Chelsea (NASDAQ: CHTP  ) would win FDA approval for its drug Northera for neurogenic orthostatic hypotension, or NOH, in multiple systems atrophy and Parkinson's patients, were dealt a disappointing blow when the FDA opted against approving the drug in 2012.

However, the FDA's willingness to consider data from another Northera phase 3 study breathed new life into Chelsea, lifting shares more than 350% in 2013.

CHTP Total Return Price Chart

CHTP Total Return Price data by YCharts.

Stumbling along the path
Chelsea acquired Northera from Dainippon Sumitomo Pharma Co., Ltd in 2006. The oral drug helps to relieve symptoms of dizziness and prevent falls tied to low blood pressure in patients with diseases associated with a malfunctioning of the autonomic nervous system -- the system that automatically controls functions in the body such as heart rate.

After ushering Northera through trials, Chelsea edged out narrow support from an FDA review panel in early 2012. That panel voted seven to four in favor of Northera in recognition of a lack of other NOH treatment options.

However, in an uncommon move a month later, the FDA cited a lack of insight into the durability of Northera's effect on patients and concerns over data collected at the study's highest enrolling site as the reasons behind rebuffing the panel's recommendation.

That decision forced Chelsea to rejigger another ongoing Northera study, known as 306B, to address the FDA's worries.

But those changes didn't put an end to Northera's troubles. After explaining the proposed changes to its 306B study, the FDA concluded a potential un-blinding of patient data presented too large a risk to the study's objectivity. As a result, the FDA determined results from 306B wouldn't be likely to provide enough evidence to support Northera's approval.

In order to preserve cash as it considered options, Chelsea began an aggressive cost-cutting program following that decision, including significant lay-offs and the removal of its founder as CEO.

Those tough decisions and the resulting lower expenses may end up positioning Chelsea for bigger profits as hopes renew for Northera's commercialization.

In February, the FDA changed its position, agreeing to use the 306B study as part of a new submission for approval. Specifically, the FDA suggested short term benefits from 306B could serve as a basis of approval if durability questions could be answered in a post-approval follow up study. That news prompted Chelsea to refile for Northera's approval this summer, resulting in an expected February 14, 2014 FDA decision date. It also prompted Chelsea to address the durability issue with the launch of a new study that enrolled its first patient in early December.

Exiting stage left
The need for new NOH therapies for MSA and Parkinson's patients remains high. As a result, the FDA has awarded Chelsea a potentially lucrative orphan designation for Northera.

That designation has been a windfall for a number of emerging biotechnology companies, including BioMarin (NASDAQ: BMRN  ) , whose $365,000 a year Naglazyme for Maroteaux-Lamy syndrome has provided the company with the firepower to roll out additional treatments including Kuvan and Aldurazyme. It also helped United Therapeutics (NASDAQ: UTHR  ) build a billion dollar a year franchise selling Remodulin, Tyvaso, and Adcirca as treatment for the rare pulmonary arterial hypertension indication.

Chelsea will get additional insight into when it may be able to profit from that designation when an FDA advisory panel evaluates Northera on January 14th, 2014. If that advisory panel supports Northera's approval again, it would be surprising if the FDA balks when it decides Northera's fate in mid February.

If Northera does win approval, it could clear the way for Chelsea broaden its addressable market by studying the drug as a treatment in other norepinephrine-related conditions and diseases, such as intradialytic hypotension, fibromyalgia and adult attention deficit hyperactivity disorder. Regardless, a positive decision would provide much needed clarity -- something that's been lacking for over a year.

A top stock to kick off 2014
There’s a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it’s one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.


Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 08, 2014, at 5:38 PM, turbojoe88 wrote:

    FDA advisory panel voted 7-4 to approve back in 2012. You can find a ton more info on the FDA's website regarding their findings

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2774246, ~/Articles/ArticleHandler.aspx, 9/21/2014 6:33:22 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 17,279.74 13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASD 4,579.79 -13.64 -0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/19/2014 3:59 PM
BMRN $69.85 Up +0.25 +0.36%
BioMarin Pharmaceu… CAPS Rating: ****
CHTP $0.00 Down +0.00 +0.00%
Chelsea Therapeuti… CAPS Rating: **
UTHR $130.12 Down -0.81 -0.62%
United Therapeutic… CAPS Rating: ****

Advertisement